Cepheid Xpert® CT/NG Reagent

The Cepheid Xpert® CT/NG Reagent is a rapid, on-demand nucleic acid amplification test (NAAT) for the detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). With same-visit PCR results, this assay enables faster clinical decision-making, reduces overtreatment and undertreatment, and minimizes patient loss to follow-up.

By integrating testing for chlamydia and gonorrhea—the most common bacterial STIs in the U.S.—into a streamlined workflow, the Xpert® CT/NG reagent supports improved patient outcomes and community health.

Clinical Relevance

• Prevalent STIs – Trichomoniasis, chlamydia, and gonorrhea remain among the most common treatable STDs in the U.S.
• Complications if untreated – infertility, pelvic inflammatory disease, pregnancy complications, and increased HIV acquisition risk.
• CDC recommendations –
  • Annual CT/NG screening for all sexually active women under 25.
  • Screening for other at-risk individuals, including MSM (men who have sex with men).
  • Testing with NAATs (PCR) as the standard of care.

Key Features

• Accurate on-demand PCR results – available during the same patient visit.
• Improved clinical workflow – reduces patient callbacks, unnecessary antibiotic use, and loss to follow-up.
• Patient-collected specimens supported – increases operational efficiency and patient comfort.
• Multiplex sample use – one patient sample can be used for CT, NG, and trichomoniasis testing.
• Enhanced patient care – same-day results reduce anxiety, improve satisfaction, and help prevent disease spread in the community.

Applications

• Rapid detection of Chlamydia trachomatis and Neisseria gonorrhoeae.
• STI screening programs in clinical and public health settings.
• Use in OB/GYN, sexual health, urology, and primary care clinics.
• Same-visit diagnosis and treatment to reduce STI transmission.
• Supporting CDC-recommended screening guidelines for at-risk populations.

The Cepheid Xpert® CT/NG Reagent delivers fast, reliable PCR-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae at the point of care. With same-visit results, compatibility with patient-collected specimens, and integration into multiplex STI testing workflows, this assay is an essential tool for improving patient outcomes, reducing antibiotic misuse, and enhancing public health STI control efforts.